Articles with public access mandates - N SrihariLearn more
Available somewhere: 22
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage …
ND James, MR Sydes, NW Clarke, MD Mason, DP Dearnaley, MR Spears, ...
The Lancet 387 (10024), 1163-1177, 2016
Mandates: Cancer Research UK, UK Medical Research Council, National Institute for …
Abiraterone for prostate cancer not previously treated with hormone therapy
ND James, JS de Bono, MR Spears, NW Clarke, MD Mason, ...
New England Journal of Medicine 377 (4), 338-351, 2017
Mandates: Cancer Research UK, UK Medical Research Council, National Institute for …
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial
CC Parker, ND James, CD Brawley, NW Clarke, AP Hoyle, A Ali, ...
The Lancet 392 (10162), 2353-2366, 2018
Mandates: Cancer Research UK, UK Medical Research Council, National Institute for …
Addition of docetaxel to hormonal therapy in low-and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial
NW Clarke, A Ali, FC Ingleby, A Hoyle, CL Amos, G Attard, CD Brawley, ...
Annals of Oncology 30 (12), 1992-2003, 2019
Mandates: Cancer Research UK, UK Medical Research Council
Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol
MR Sydes, MR Spears, MD Mason, NW Clarke, DP Dearnaley, ...
Annals of Oncology 29 (5), 1235-1248, 2018
Mandates: Cancer Research UK, UK Medical Research Council, National Institute for …
Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised …
G Attard, L Murphy, NW Clarke, W Cross, RJ Jones, CC Parker, ...
The lancet 399 (10323), 447-460, 2022
Mandates: Cancer Research UK, UK Medical Research Council, National Institute for …
Failure-free survival and radiotherapy in patients with newly diagnosed nonmetastatic prostate cancer: data from patients in the control arm of the STAMPEDE trial
ND James, MR Spears, NW Clarke, DP Dearnaley, MD Mason, CC Parker, ...
JAMA oncology 2 (3), 348-357, 2016
Mandates: Cancer Research UK, UK Medical Research Council, National Institute for …
Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial
ND James, MR Sydes, MD Mason, NW Clarke, J Anderson, DP Dearnaley, ...
The lancet oncology 13 (5), 549-558, 2012
Mandates: Cancer Research UK
Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab
S Lin, NA Kennedy, A Saifuddin, DM Sandoval, CJ Reynolds, RC Seoane, ...
Nature communications 13 (1), 1379, 2022
Mandates: Versus Arthritis, UK, Cancer Research UK, UK Medical Research Council …
Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial
CC Parker, ND James, CD Brawley, NW Clarke, A Ali, CL Amos, G Attard, ...
PLoS medicine 19 (6), e1003998, 2022
Mandates: Cancer Research UK, UK Medical Research Council, National Institute for …
Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5‐year follow‐up results from the STAMPEDE randomised trial (NCT00268476)
ND James, NW Clarke, A Cook, A Ali, AP Hoyle, G Attard, CD Brawley, ...
International Journal of Cancer 151 (3), 422-434, 2022
Mandates: Canadian Institutes of Health Research, Cancer Research UK, UK Medical …
Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): An open-label, non …
JE Brown, KL Royle, W Gregory, C Ralph, A Maraveyas, O Din, T Eisen, ...
The Lancet Oncology 24 (3), 213-227, 2023
Mandates: US National Institutes of Health, Cancer Research UK, National Institute for …
Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two …
G Attard, L Murphy, NW Clarke, A Sachdeva, C Jones, A Hoyle, W Cross, ...
The Lancet Oncology 24 (5), 443-456, 2023
Mandates: Cancer Research UK, UK Medical Research Council, National Institute for …
Addition of docetaxel to first-line long-term hormone therapy in prostate cancer (STAMPEDE): modelling to estimate long-term survival, quality-adjusted survival, and cost …
BS Woods, E Sideris, MR Sydes, MR Gannon, MKB Parmar, M Alzouebi, ...
European urology oncology 1 (6), 449-458, 2018
Mandates: Cancer Research UK, UK Medical Research Council, National Institute for …
Results of a multicentre randomised controlled trial of cochlear-sparing intensity-modulated radiotherapy versus conventional radiotherapy in patients with parotid cancer …
CM Nutting, JP Morden, M Beasley, S Bhide, A Cook, E De Winton, ...
European Journal of Cancer 103, 249-258, 2018
Mandates: Cancer Research UK, National Institute for Health Research, UK
Observation versus screening spinal MRI and pre-emptive treatment for spinal cord compression in patients with castration-resistant prostate cancer and spinal metastases in the …
D Dearnaley, V Hinder, A Hijab, G Horan, N Srihari, P Rich, JG Houston, ...
The Lancet Oncology 23 (4), 501-513, 2022
Mandates: US National Institutes of Health, Cancer Research UK, National Institute for …
Thromboxane biosynthesis in cancer patients and its inhibition by aspirin: a sub-study of the Add-Aspirin trial
N Joharatnam-Hogan, D Hatem, FH Cafferty, G Petrucci, DA Cameron, ...
British Journal of Cancer 129 (4), 706-720, 2023
Mandates: Cancer Research UK, UK Medical Research Council, National Institute for …
Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in …
CC Parker, H Kynaston, AD Cook, NW Clarke, CN Catton, WR Cross, ...
The Lancet 403 (10442), 2416-2425, 2024
Mandates: Cancer Research UK, UK Medical Research Council, National Institute for …
Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the …
CC Parker, NW Clarke, AD Cook, H Kynaston, CN Catton, WR Cross, ...
The Lancet 403 (10442), 2405-2415, 2024
Mandates: Cancer Research UK, UK Medical Research Council, National Institute for …
Runs of homozygosity and testicular cancer risk
C Loveday, A Sud, K Litchfield, M Levy, A Holroyd, P Broderick, ...
Andrology 7 (4), 555-564, 2019
Mandates: US National Institutes of Health, Cancer Research UK, National Institute for …
Publication and funding information is determined automatically by a computer program